Your browser doesn't support javascript.
High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.
Menezes, Ana M B; Victora, Cesar G; Hartwig, Fernando P; Silveira, Mariângela F; Horta, Bernardo L; Barros, Aluísio J D; Mesenburg, Marilia A; Wehrmeister, Fernando C; Pellanda, Lúcia C; Dellagostin, Odir A; Struchiner, Cláudio J; Burattini, Marcelo N; Barros, Fernando C; Hallal, Pedro C.
  • Menezes AMB; Universidade Federal de Pelotas, Pelotas, Brazil. anamene.epi@gmail.com.
  • Victora CG; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Hartwig FP; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Silveira MF; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Horta BL; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Barros AJD; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Mesenburg MA; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Wehrmeister FC; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Pellanda LC; Fundação Universidade Federal de Ciências de Saúde de Porto Alegre, Porto Alegre, Brazil.
  • Dellagostin OA; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Struchiner CJ; Fundação Getúlio Vargas, Rio de Janeiro, Brazil.
  • Burattini MN; Universidade de São Paulo, São Paulo, Brazil.
  • Barros FC; Universidade Federal de Pelotas, Pelotas, Brazil.
  • Hallal PC; Universidade Federal de Pelotas, Pelotas, Brazil.
Sci Rep ; 11(1): 13279, 2021 06 24.
Article in English | MEDLINE | ID: covidwho-1281742
ABSTRACT
Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic. Using data from the recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportion of people with and without antibodies for SARS-CoV-2 who were asymptomatic, which symptoms were most frequently reported, number of symptoms and the association with socio-demographic characteristics. We tested 33,205 subjects using a rapid antibody test previously validated. Information was collected before participants received the test result. Out of 849 (2.7%) participants positive for SARS-CoV-2 antibodies, only 12.1% (95% CI 10.1-14.5) reported no symptoms, compared to 42.2% (95% CI 41.7-42.8) among those negative. The largest difference between the two groups was observed for changes in smell/taste (56.5% versus 9.1%, a 6.2-fold difference). Changes in smell/taste, fever and body aches were most likely to predict positive tests as suggested by recursive partitioning tree analysis. Among individuals without any of these three symptoms, only 0.8% tested positive, compared to 18.3% of those with both fever and changes in smell or taste. Most subjects with antibodies against SARS-CoV-2 are symptomatic, even though most present only mild symptoms.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / Carrier State / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: South America / Brazil Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-92775-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / Carrier State / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: South America / Brazil Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-92775-y